MARC 2
Laufzeit: 01.01.2012 - 31.12.2013
Kurzfassung
An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy
Laufzeit: 01.01.2012 - 31.12.2013
An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy
